The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 8)
Research Grant, 2016
GBA Meta-analysis Initiative: Charting a Path to Success for Clinical Trials in Patients with GBA-PD
Promising Outcomes of Original Grant:
We ascertained the associations between GBA mutations and cognitive and motor outcomes in seven large cohorts representing 2,304 patients with PD (including 221 carrying a GBA mutation) and 20,868 longitudinal study visits conducted in England, the Netherlands, France, Canada and the United States. This study found that GBA mutations hasten the longitudinal pro...
Research Grant, 2016
Nilotinib, a drug approved for chronic myelogenous leukemia, inhibits the protein c-Abl. Higher brain levels of c-Abl are associated with Parkinson's disease (PD), and laboratory studies have linked c-Abl to cellular pathways believed to underlie PD. Nilotinib has also shown protective effects in PD preclinical models. Additionally, a small Phase I trial reported nilotinib was we...
Researchers: Tanya Simuni, MD
Clinical Intervention Awards, 2012
The purpose of this study is to provide safety data related to enhancements in the clinical delivery procedure for administering Adeno-Associated Virus Encoding Human Aromatic L-Amino Acid Decarboxylase (AAV2-hAADC) gene therapy in Parkinson's disease (PD) patients. A previous clinical study investigated low and moderate doses of AADC gene therapy. Safety end points were achie...
Repositioning Drugs for PD, 2012
Parkinson's disease (PD) causes well known motor symptoms of tremor, slowness and stiffness, but also leads to cognitive impairment. Research has shown that early loss of cells in a brain structure called the norepinephrine-locus ceruleus in PD corresponds with the development of cognitive deficits and is a novel target for PD therapeutics. Atomoxetine (ATM) is a specific norep...
Researchers: Vanessa K. Hinson, MD, PhD
Research Grant, 2012
Cognitive impairment is a symptom seen in Parkinson's disease (PD) patients, and some can progress to dementia. AVE8112 is a PDE4 inhibitor that was in development by the pharmaceutical company Sanofi for the treatment of cognitive impairment in Alzheimer's disease patients and had shown promise in several pre-clinical models. The Michael J. Fox Foundation partnered with Sanofi...
Researchers: Research Staff of The Michael J. Fox Foundation,